Is Artemis Medicare overvalued or undervalued?

As of 1 October 2025, the valuation grade for Artemis Medicare has moved from attractive to very attractive, indicating a positive shift in its perceived value. The company is currently considered undervalued. Key ratios include a PE ratio of 37.38, an EV to EBITDA of 20.10, and a PEG ratio of 0.70, which suggests that the stock may be priced favorably relative to its growth potential.
In comparison to its peers, Artemis Medicare stands out with a significantly lower PE ratio than Max Healthcare, which has a PE of 89.97, and Apollo Hospitals, which has a PE of 68.03. The company's return on capital employed (ROCE) is 14.56%, further supporting its strong operational efficiency relative to competitors. Despite a recent decline in stock performance compared to the Sensex, with a year-to-date return of -25.22% versus the Sensex's 3.64%, the long-term outlook remains promising given its historical performance over three and five years.